drugset / Trial / NCT00329355

Menstrual Migraine Treatment With TREXIMET (Formerly Known as TREXIMA)

NCT00329355

Phase 3 Completed 351 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindTreatment

Summary

This study was designed to determine efficacy of TREXIMET (sumatriptan/naproxen sodium), formerly known as TREXIMA compared to placebo for the treatment of a menstrual migraine.

Timeline

Start
2006-05
Primary completion
2006-11
Completion
2006-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Naproxen Small molecule 500 mg Oral
Subject Sumatriptan Unknown 85 mg Oral

Indications